Recent insights: Mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome.

F1000Research

Volumn 5, Issue , 2016, Pages

  Horie, Shahd ^a   Laffey, John G ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOTENSIN CONVERTING ENZYME 2; ESCHERICHIA COLI ENDOTOXIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; KERATINOCYTE GROWTH FACTOR; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; PROSTAGLANDIN E2; PROTEIN BCL XL; SOMATOMEDIN C; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANGIOGENESIS; CELL INTERACTION; CELL TRANSPLANTATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE SEVERITY; ESCHERICHIA COLI PNEUMONIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG INJURY; LUNG LAVAGE; MEMBRANE MICROPARTICLE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELL TRANSPLANTATION; NEUTROPHIL; NONHUMAN; NUCLEAR REPROGRAMMING; PARACRINE SIGNALING; PATHOGENESIS; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PSEUDOMONAS PNEUMONIA; REVIEW; UMBILICAL CORD BLOOD; VENTILATOR INDUCED LUNG INJURY;

EID: 85010911740     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8217.1     Document Type: Review

References (38)

1. Bellani G, Laffey JG, Pham T, et al.: Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016; 315(8): 788-800.
2. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al.: Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23): 2526-33.
3. Fanelli V, Vlachou A, Ghannadian S, et al.: Acute respiratory distress syndrome: new definition, current and future therapeutic options. J Thorac Dis. 2013; 5(3): 326-34.
4. Ding DC, Shyu WC, Lin SZ: Mesenchymal stem cells. Cell Transplant. 2011; 20(1): 5-14.
5. Gupta N, Su X, Popov B, et al.: Intrapulmonary delivery of bone marrowderived mesenchymal stem cells improves survival and attenuates endotoxininduced acute lung injury in mice. J Immunol. 2007; 179(3): 1855-63.
6. Mei SH, McCarter SD, Deng Y, et al.: Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007; 4(9): e269.
7. Chang YS, Oh W, Choi SJ, et al.: Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant. 2009; 18(8): 869-86.
8. Nemeth K, Leelahavanichkul A, Yuen PS, et al.: Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009; 15(1): 42-9.
9. Lee JW, Fang X, Gupta N, et al.: Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A. 2009; 106(38): 16357-62.
10. Krasnodembskaya A, Song Y, Fang X, et al.: Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010; 28(12): 2229-38.
11. Curley GF, Hayes M, Ansari B, et al.: Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax. 2012; 67(6): 496-501.
12. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105(4): 1815-22.
13. Beyth S, Borovsky Z, Mevorach D, et al.: Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005; 105(5): 2214-9.
14. Aguilar S, Scotton CJ, McNulty K, et al.: Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One. 2009; 4(11): e8013.
15. Giacca M, Zacchigna S: VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther. 2012; 19(6): 622-9.
16. Shalaby SM, El-Shal AS, Abd-Allah SH, et al.: Mesenchymal stromal cell injection protects against oxidative stress in Escherichia coli-induced acute lung injury in mice. Cytotherapy. 2014; 16(6): 764-75.
17. Devaney J, Horie S, Masterson C, et al.: Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax. 2015; 70(7): 625-35.
18. Asmussen S, Ito H, Traber DL, et al.: Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax. 2014; 69(9): 819-25.
19. Chimenti L, Luque T, Bonsignore MR, et al.: Pre-treatment with mesenchymal stem cells reduces ventilator-induced lung injury. Eur Respir J. 2012; 40(4): 939-48.
20. Curley GF, Ansari B, Hayes M, et al.: Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology. 2013; 118(4): 924-32.
21. Hayes M, Masterson C, Devaney J, et al.: Therapeutic efficacy of human mesenchymal stromal cells in the repair of established ventilator-induced lung injury in the rat. Anesthesiology. 2015; 122(2): 363-73.
22. Lee JW, Krasnodembskaya A, McKenna DH, et al.: Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med. 2013; 187(7): 751-60.
23. McAuley DF, Curley GF, Hamid UI, et al.: Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014; 306(9): L809-15.
24. He HL, Liu L, Chen QH, et al.: MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol. 2015; 230(3): 691-701.
25. Min F, Gao F, Li Q, et al.: Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. Mol Med Rep. 2015; 11(4): 2387-96.
26. Martinez-Gonzalez I, Roca O, Masclans JR, et al.: Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol. 2013; 49(4): 552-62.
27. Su VY, Yang KY: Mesenchymal stem cell-conditioned medium induces neutrophils apoptosis via inhibition of NF-kB pathway and increases endogenous pulmonary stem cells in endotoxin-induced acute lung injury. European Respiratory Journal. 2015, 46(suppl 59): OA3520.
28. Ionescu L, Byrne RN, van Haaften T, et al.: Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol. 2012; 303(11): L967-77.
29. Hayes M, Curley GF, Masterson C, et al.: Mesenchymal stromal cells are more effective than the MSC secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury. Intensive Care Med Exp. 2015; 3(1): 29.
30. Zhu YG, Feng XM, Abbott J, et al.: Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2014; 32(1): 116-25.
31. Islam MN, Das SR, Emin MT, et al.: Mitochondrial transfer from bonemarrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012; 18(5): 759-65.
32. Monsel A, Zhu YG, Gennai S, et al.: Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med. 2015; 192(3): 324-36.
33. Jackson MV, Morrison TJ, O'Kane CM, et al.: T3 Mitochondrial transfer is an important mechanism by which Mesenchymal Stromal Cells (MSC) facilitate macrophage phagocytosis in the in vitro and in vivo models of Acute Respiratory Distress Syndrome (ARDS). Thorax. 2015; 70(Suppl 3): A1.3-A2.
34. Wilson JG, Liu KD, Zhuo H, et al.: Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015; 3(1): 24-32.
35. Zheng G, Huang L, Tong H, et al.: Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014; 15(1): 39.
36. Bertolo A, Gemperli A, Gruber M, et al.: In vitro cell motility as a potential mesenchymal stem cell marker for multipotency. Stem Cells Transl Med. 2015; 4(1): 84-90.
37. Tashiro J, Elliot SJ, Gerth DJ, et al.: Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res. 2015; 166(6): 554-67.
38. Bustos ML, Huleihel L, Kapetanaki MG, et al.: Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response. Am J Respir Crit Care Med. 2014; 189(7): 787-98.